Boston Scientific has announced new data backing its Farapulse pulsed field ablation (PFA) platform for treating AFib.
Field Medical announced the presentation of clinical data from the first-in-human study of its FieldForce pulsed field ...
Abbott on Friday presented one-year clinical trial results for the Volt pulsed field ablation system alongside six-month CE ...
Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation ...
Medical Device Network on MSN
Abbott initiates UK pilot of Volt PFA system
Abbott’s Volt pulsed-field ablation (PFA) system will be trialled across 15 NHS sites for the treatment of atrial fibrillation.
Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex ...
NHS hospitals are to trial an innovative new treatment for people with a common heart condition. The device uses electrical pulses to target and destroy heart tissue and stop irregular heart rhythms ...
At 1 year, nearly 80% of patients with atrial fibrillation treated with an FDA-approved spherical pulsed field ablation ...
Abbott (NYSE: ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the ...
Boston Scientific’s electrophysiology business stumbled as competition from Medtronic, Johnson & Johnson, Abbott, and others ...
Boston Scientific leads the pulsed field ablation (PFA) technology market to treat atrial fibrillation (Afib). But it is by no means alone in its commitment to this relatively new way to treat some ...
PFA was noninferior to cryoablation for first recurrence of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation. Tissue-selective energy delivery and short application times offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results